Arthneeti
Anuh Pharma Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
AP

Anuh Pharma Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Anuh Pharma Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹186Cr
+12% YoY
Net profit
₹8Cr
−46.7% YoY
Margin
6%
−4 pp YoY

Anuh Pharma Ltd Q2 FY26 key numbers

Revenue
Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. 185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. 372.36 Cr, up 22.54% year-on-year from Rs. 303.86 Cr.

As stated in Anuh Pharma Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Anuh Pharma Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. 185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. 372.36 Cr, up 22.54% year-on-year from Rs. 303.86 Cr. EBITDA for the quarter ended 30/09/2025: Rs. 12.86 Cr, down 6.00% QoQ; margin: 6.92%.

From Anuh Pharma Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. 185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. 372.36 Cr, up 22.54% year-on-year from Rs. 303.86 Cr.
  • Revenue for H1 FY 2025: Rs. 310.98 Cr; H1 FY 2026: Rs. 376.73 Cr, up 21.14% year-on-year.
  • Domestic and export sales split shows growth: H1 FY26 total 371 Cr vs H1 FY25 total 302 Cr.

2 more points from Anuh Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Added a new intermediate block, increasing to 2 intermediate blocks and 9 API blocks, with total reactor capacity now at 240 KL. (Operational as of H1 FY26)
  • Effluent treatment capacity increased from 100 KL/day to 150 KL/day to support higher production volumes. (Completed as of H1 FY26)
  • Commissioned new solar power capacity to support cleaner energy use and reduce operational costs. (Completed as of H1 FY26)
  • Other facilities include a Zero Liquid Discharge Effluent Control system (treating 100% generated pollution), green belt for carbon footprint reduction, 100% power backup via dedicated line, and latest fire safety measures, indicating ongoing infrastructure investments without stated costs or timelines.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anuh Pharma Ltd Q2 FY26 results — key figures

Anuh Pharma Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue186166+12%1860%
Operating profit (EBITDA)1217-29.4%10+20%
Operating margin6%10%-4 pp6%0 pp
Profit before tax1018-44.4%11-9.1%
Net profit (PAT)815-46.7%80%
EPS (₹)0.761.50-49.3%0.83-8.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Anuh Pharma's management said in earlier quarters

Earlier calls (5)

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q2 FY26 results?

Q2 FY 2025-26 (3 months ended 30/09/2025) Operating Revenue: Rs. 185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. 372.36 Cr, up 22.54% year-on-year from Rs. 303.86 Cr. EBITDA for the quarter ended 30/09/2025: Rs. 12.86 Cr, down 6.00% QoQ; margin: 6.92%.

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

Added a new intermediate block, increasing to 2 intermediate blocks and 9 API blocks, with total reactor capacity now at 240 KL.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.